2. In the Misuse of Drugs Act 1973, in the First Schedule —(a) | in Part 1, in paragraph 16, after item (8AB), insert — | 1-(3-Chlorophenyl)-2-(methylamino)propan-1-one (also known as 3-chloromethcathinone or 3‑CMC)”; |
|
|
| (b) | in Part 1, in paragraph 18, after item (1), insert — | N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (also known as ADB-INACA or ADMB-INACA) and its N‑(1‑amino‑1‑oxohexan‑2‑yl) isomers”; |
|
|
| (c) | in Part 1, in paragraph 18, replace item (16A) with — | 1-(1-(1-(4-Bromophenyl)ethyl)-piperidin-4-yl)- 1,3-dihydro-2H-benzimidazol-2-one (also known as Brorphine) and its bromo positional isomers in the phenyl ring”; |
|
|
| (d) | in Part 1, in paragraph 18, after item (43A), insert — | N-Ethyl-1-(3-methoxyphenyl)-cyclohexanamine (also known as 3-Methoxyeticyclidine or 3‑Methoxy‑PCE or 3-MeO-PCE) and its methoxy positional isomers in the phenyl ring |
| | 2-(Ethylamino)-2-(2-fluorophenyl)-cyclohexanone (also known as 2-fluorodeschloro-N-ethyl-ketamine, 2‑FDCNEK, 2-fluoro-2-oxo PCE or 2‑fluoro NENDCK) and its fluoro positional isomers in the phenyl ring”; |
|
|
| (e) | in Part 1, in paragraph 18, after item (57), insert — | 2-(1H-Indazole-3-carboxamido)- 3,3-dimethylbutanoic acid and its hexanoic acid isomers”; |
|
|
| (f) | in Part 1, in paragraph 19, after item (10), insert — | 5,6-Dimethoxy-N,N-diisopropyltryptamine (also known as 5,6-Dimethoxy-DiPT or 5,6‑MeO‑DiPT)”; |
|
|
| (g) | in Part 1, in paragraph 21, after item (10), insert — | N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (4,5-dihydroxypentyl)-1H-indazole-3-carboxamide”; |
|
|
| (h) | in Part 1, in paragraph 21, after item (13), insert — | N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-hydroxycyclohexylmethyl)-1H-indazole-3-carboxamide |
| | N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (pent-4-en-1-yl)-1H-indazole-3-carboxamide (also known as ADB-4en-PINACA, ADMB-4en-PINACA or ADB‑PENINACA)”; |
|
|
| (i) | in Part 1, in paragraph 21, after item (36B), insert — | Methyl 2-(1-butyl-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate (also known as MDMB‑BUTINACA or MDMB-BINACA)”; and |
|
|
| (j) | in Part 4, in the definition of “cannabinol derivatives”, after “tetrahydro” wherever it appears, insert “or hexahydro”. |
|